Alkermes Plc (NASDAQ: ALKS)
Alkermes Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Alkermes Plc Company Info
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
News & Analysis
Why Alkermes Stock Is Sinking Today
The biotech company's Q3 revenue and earnings looked great, but the results weren't enough to wow investors.
Why Alkermes Stock Is Jumping Today
The drugmaker beat Wall Street's expectations with its Q1 results.
Why Alkermes Stock Blasted 15% Higher Today
The biotech smashed analyst estimates in its final quarter of 2021.
Why Alkermes Stock Is Sinking Today
Johnson & Johnson partly ended two licensing agreements with the company.
Why Shares of Alkermes Rose 18% Last Month
An agreement with an activist investor capped a busy month.
Want to Make Money in Biotech? Do This First
Keeping track of upcoming events is important.
Why Alkermes' Q4 Results Were Better Than They Might Seem
The biotech posted a big year-over-year sales decline. But there was a good reason for it.
Here's Why Alkermes Shares Jumped Higher Today
The biotech has a plan to increase profitability.
Valuation
Earnings Transcripts
Alkermes (ALKS) Q2 2022 Earnings Call Transcript
ALKS earnings call for the period ending June 30, 2022.
Alkermes (ALKS) Q1 2022 Earnings Call Transcript
ALKS earnings call for the period ending March 31, 2022.
Alkermes (ALKS) Q4 2021 Earnings Call Transcript
ALKS earnings call for the period ending December 31, 2021.
Alkermes plc (ALKS) Q3 2021 Earnings Call Transcript
ALKS earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.